CAH Stock Chart & Stats
$3955.00
$0.00(0.00%)
At close: 4:00 PM EDT
$3955.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2,729.00 - $4,257.49
Previous CloseN/A
Volume0.00
Average Volume (3M)200.00
Market Cap
$960.06B
Enterprise Value$61.08B
Total Cash (Recent Filing)$4.86B
Total Debt (Recent Filing)$9.95B
Price to Earnings (P/E)31.4
Beta-0.35
Next Earnings
Nov 05, 2026EPS Estimate
53.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.27
Shares Outstanding231,559,340
10 Day Avg. Volume369
30 Day Avg. Volume200
Financial Highlights & Ratios
PEG Ratio2.68
Price to Book (P/B)-19.45
Price to Sales (P/S)0.22
P/FCF Ratio12.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4,885.73Price Target Upside23.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)222.45
Revenue Forecast (FY)$4.71T
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationStrong operating and free cash flow demonstrate effective cash conversion in a high-volume distribution model. This provides funding for investment, debt service, and shareholder returns while giving Cardinal flexibility to manage working-capital swings and sustain operations through changing conditions.
Broad Revenue And Profit MomentumMeaningful revenue expansion, improving profitability, and above-target FY27 EPS guidance indicate that growth is supported across multiple businesses rather than by a single isolated result. Continued Pharma, Specialty, and Other segment momentum can reinforce scale advantages and earnings compounding.
Long-term CVS Distribution AgreementExtending the CVS distribution relationship through 2032 preserves an important customer partnership and improves visibility into future distribution activity. Maintaining the existing scope supports Cardinal’s market position, reinforces network scale, and provides a durable base for executing its growth plans.
Bears Say
Negative Equity And Rising DebtPersistently negative equity and higher debt weaken financial flexibility and make the capital structure more dependent on continued cash generation. Greater leverage can constrain future investment and capital allocation, while leaving less room to absorb operating setbacks or unfavorable changes in financing conditions.
Structurally Low MarginsVery thin margins leave limited room for execution errors, pricing pressure, or cost increases to be absorbed without affecting earnings. Because small changes in product mix, purchasing economics, and operating expenses can materially influence profit, sustaining returns requires consistent efficiency at scale.
Regulatory And Cost PressuresRegulatory changes affecting IRA and 340B economics can pressure pharmaceutical volumes and pricing, while fuel and resin inflation can raise operating costs. These pressures may limit margin expansion and make the earnings outlook more sensitive to reimbursement rules, input prices, and execution.
Cardinal Health News
CAH FAQ
What was Cardinal Health’s price range in the past 12 months?
Cardinal Health lowest stock price was $2729.00 and its highest was $4257.49 in the past 12 months.
What is Cardinal Health’s market cap?
Cardinal Health’s market cap is $960.06B.
When is Cardinal Health’s upcoming earnings report date?
Cardinal Health’s upcoming earnings report date is Nov 05, 2026 which is in 31 days.
How were Cardinal Health’s earnings last quarter?
Cardinal Health released its earnings results on Aug 11, 2026. The company reported $52.848 earnings per share for the quarter, beating the consensus estimate of $43.949 by $8.899.
Is Cardinal Health overvalued?
According to Wall Street analysts Cardinal Health’s price is currently Undervalued.
Does Cardinal Health pay dividends?
Cardinal Health does not currently pay dividends.
What is Cardinal Health’s EPS estimate?
Cardinal Health’s EPS estimate is 53.52.
How many shares outstanding does Cardinal Health have?
Cardinal Health has 231,559,340 shares outstanding.
What happened to Cardinal Health’s price movement after its last earnings report?
Cardinal Health reported an EPS of $52.848 in its last earnings report, beating expectations of $43.949. Following the earnings report the stock price went up 1.138%.
Which hedge fund is a major shareholder of Cardinal Health?
Currently, no hedge funds are holding shares in MX:CAH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardinal Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4,885.73 (23.53% Upside)
$4,885.73 (23.53% Upside)
Blogger Sentiment
Bullish
MX:CAH Sentiment 76%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $1.1B over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.43%
12-Months-Change
Fundamentals
Return on Equity
0.89%
Trailing 12-Months
Asset Growth
7.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cardinal Health
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
CAH Company Deck
CAH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong, broad-based fiscal '26 performance across revenue, profit, EPS (Q4 EPS +40% YoY) and cash flow ($5B adjusted FCF), with clear operational momentum in Pharma, Specialty and Other growth businesses and disciplined capital return (share buybacks and increased repurchase authorization). Key risks highlighted include reliance on a nonrecurring $100M IEEPA tariff refund that materially boosted GMPD profitability and $0.31 of Q4 EPS, input cost pressures (fuel and commodity resins), regulatory headwinds (IRA/340B impacts ~500 bps mentioned), and expected near-term cadence softness (Q1 FY27 headwind). Overall, positives around scale, cash generation, segment momentum and reconfirmed long‑term targets materially outweigh the transitory and manageable challenges discussed.View all MX:CAH earnings summariesCAH Revenue Breakdown
91.94% Pharmaceutical and Specialty Solutions
5.68% Global Medical Products and Distribution
2.42% Other
-0.04% Corporate

CAH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$4,885.73
▲(23.53% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month










